Literature DB >> 21883402

Epidermotropic CD8+ cytotoxic T-cell lymphoma exhibiting a transition from the indolent to the aggressive phase, accompanied by emergence of CD7+ cells and formation of neutrophilic pustules.

Y Ito1, M Goto, Y Hatano, M Kawamoto, M Ohishi, S Takayasu, K Katagiri, S Fujiwara.   

Abstract

A 47-year-old-man presented with rashes on his trunk and limbs, and a diagnosis of parapsoriasis was made. Ten years later, the rashes had progressed gradually to form plaques and tumours. Gene rearrangement studies revealed monoclonality of the T-cell receptor β-chain (TCR-Jβ)1 gene, and results of flow cytometry and immunohistochemical examination confirmed a diagnosis of epidermotropic CD8+ cytotoxic T-cell lymphoma. The clinical course of the disease remained indolent for some time, but about 2 years later, neutrophilic pustules formed on the surface of the skin lesions, and tumours developed in the patient's testes. Using flow cytometry, emergence of CD7+ cells was found. The patient died the following year of respiratory failure due to brain herniation. On postmortem examination, CD8+ tumour cells were found in the brain. This case demonstrates an unusually protracted indolent phase in a patient with cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma; its transition into the aggressive phase was accompanied by emergence of CD7+ cells and formation of neutrophilic pustules. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883402     DOI: 10.1111/j.1365-2230.2011.04160.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  1 in total

1.  Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma.

Authors:  Quinto Gesiotto; Yumeng Zhang; Ayesha Malik; Lucia Seminario-Vidal; Ernesto Ayala; Ling Zhang; Lubomir Sokol
Journal:  Cureus       Date:  2021-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.